All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
On January 10, 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold across all trials investigating allogeneic chimeric antigen receptor (allo-CAR) T-cell therapies.1 The clinical hold was introduced in October 2021 after it was reported that one patient with pretreated stage IV follicular lymphoma showed evidence of a chromosomal abnormality after receiving ALLO-501A CAR T cells in the phase I/II ALPHA2 study (NCT04416984). However, investigators confirmed that this was unrelated to any alloCAR-T product or the manufacturing process and had no clinical significance. The abnormality was an isolated event and was not detected in any other patient treated with the same ALLO-501A lot.
Clinical trials within the alloCAR-T platform are due to resume with the phase II trial of ALLO-501A in relapsed/refractory large B-cell lymphoma, it is expected to commence in mid-year 2022 pending discussions with the FDA. The clinical hold affected five alloCAR T trials designed to treat non-Hodgkin lymphoma and R/R multiple myeloma.
Allo-CAR T cells are derived from induced pluripotent stem cells from healthy donors that are genetically modified using the transcription activator-like effector nucleases (TALEN) gene-editing technology.
ALPHA study: First-in-human data of ALLO-501 and ALLO-647 in R/R large B-cell or follicular lymphoma
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to Sattva Neelapu, MD Anderson Cancer...
FDA places a clinical hold on allogeneic CAR T cell trials
On October 7, 2021, the U.S. Food and Drug Administration (FDA) placed a clinical hold on a series of trials investigating the use of allogeneic chimeric antigen receptor (allo-CAR) T-cell...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox